Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis

• DOI: 10.3389/fcvm.2021.691907
• Publication Date: 2021-07-14T05:03:43Z
• Authors: Gloria M. Gager; Georg Gelbenegger; Bernd Jilma; Dirk von Lewinski; Harald Sourij; Ceren Eyileten; Krzysztof Filipiak; Marek Postula; Jolanta M. Siller...
• Keywords: Concomitant; Empagliflozin

Background: Sodium–glucose co-transporter 2 (SGLT2) inhibitors are an emerging class of glucose-lowering drugs that have become increasingly relevant for the treatment and prevention heart failure (HF). Therefore, we aimed to investigate various SGLT2 in patients with established HF at baseline focused on different types HF. Methods: An extensive search PubMed Web Science until January 2021 was done. Two reviewers, independently duplicate, applied selection criteria. This meta-analysis conducted according PRISMA guidelines. Data were pooled using a random-effects model. Randomized controlled trials (RCTs) vs. comparator reporting clinical outcomes included. The primary efficacy outcome composite hospitalization (HHF) or cardiovascular (CV) mortality. All-cause mortality, CV HHF considered as secondary endpoints. Subgroup analyses involving status diabetes, type HF, administered inhibitor, sex, age, body mass index (BMI), estimated glomerular filtration rate (eGFR), cause concomitant medication performed. Results: Seventeen RCTs, comprising total 20,749 participants, included ( n = 10,848 treated 9,901 comparator). Treatment population associated 27% relative risk reduction (RRR) mortality [risk ratio (RR) 0.73, 95% CI 0.68–0.78], 32% RRR (RR 0.68, 0.62–074), 18% 0.82, 0.73–0.91), 17% all-cause 0.83, 0.75–0.91). effect endpoint consistent among gliflozines. independent underlying diabetes mellitus, BMI, renal function, type. Conclusions: improved